Nomura initiates coverage on this recently-listed CRDMO stock, sees 18% upside despite 22% correction

Nomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positioning, diversified capabilities, and robust revenue and earnings growth projections despite recent stock correction.